2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

Catalog No. :
ACJAIR052
CAS No. :
1310384-96-3
Molecular Formula :
C15H24BN3O2
Molecular Weight :
289.19

IUPAC Name:2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
IUPAC Name2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
Molecular FormulaC15H24BN3O2
Molecular Weight289.19
SMILESCC1(C)C(C)(C)OB(C2=CN=C(N3CCCCC3)C=N2)O1
InChI KeyYVKBIAXUBLNZEY-UHFFFAOYSA-N
Synonym2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine;Pyrazine, 2-(1-piperidinyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1310384-96-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACJAIR052 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJAIR052 route product structure diagram
    ACJAIR0521310384-96-3
Inquiry

2. ACJAIR052 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACUVOH504 route compound structure diagram
    ACUVOH5041060803-86-2 In Stock
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACJAIR052 route product structure diagram
    ACJAIR0521310384-96-3
Inquiry

Comments (0)